Diabetic medicine : a journal of the British Diabetic Association
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.
Liraglutide (NN2211) is a long-acting GLP-1 analogue, with a pharmacokinetic profile suitable for once-daily administration. This multicentre, double-blind, parallel-group, double-dummy study explored the dose-response relationship of liraglutide effects on bodyweight and glycaemic control in subjects with Type 2 diabetes. ⋯ Once-daily liraglutide improved glycaemic control and weight, in a comparable degree to metformin. Liraglutide appeared to be safe and generally well tolerated. Higher doses of liraglutide merit study in future clinical trials.
-
To evaluate the dissemination of patient-oriented evidence that matters (POEMs) derived from the UK Prospective Diabetes Study (UKPDS) through health information websites. ⋯ The dissemination of POEMs through the Internet is poor. If patients are to be involved in decision-making processes, efforts should be made to update the Internet contents to meet this challenge.
-
To characterize the epidemiology of rodent bite foot injuries in patients presenting to a diabetes clinic in Tanzania. ⋯ Diabetes patients with peripheral neuropathy are at increased risk of bite injuries in areas with large rodent populations. Preventive efforts should include covering the feet at bedtime, and daily feet examination by patient or relatives.
-
To evaluate the relation between common variants in the ATP-sensitive K+ channel genes and glucose intolerance. ⋯ The common KCNJ11 E23K gene variant, but not the ABCC8 exon 16 or exon 18 variant, was consistently associated with Type 2 diabetes.